Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Probiotic bacteria" is a nonspecific, umbrella term referring to a diverse group of live microorganisms, primarily from genera such as *Lactobacillus*, *Bifidobacterium*, *Saccharomyces*, and others, which when administered in adequate amounts confer documented health benefits on the host. These are not single-molecule therapeutic targets but collections of microbial species and strains, each with distinct taxonomy, physiological traits, and mechanisms of action. Probiotics are most commonly applied to prevent or treat gastrointestinal disorders, restore microbial balance, support immune function, and act as adjuncts in the management of a variety of diseases. Accurate identification of probiotic strains is essential, often including genus, species, and strain designation. Notably, the term is too broad and not suitable for use as a canonical drug target without specifying organism and strain.
Antagonism of pathogenic microbes by colonization/competition; Enhancement of host immune responses (e.g., stimulation of regulatory T cells, cytokine modulation); Restoration of microbial and metabolic balance in the gut; Production of antimicrobial peptides and metabolites
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probiotic bacteria.